Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.

[1]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  J. Eikenboom,et al.  von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients , 2020, Thrombosis and Haemostasis.

[3]  F. Leebeek,et al.  Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  F. Leebeek,et al.  Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? , 2018, Blood reviews.

[5]  K. Batt,et al.  Real‐world resource use and costs of haemophilia A‐related bleeding , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  F. Leebeek,et al.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients , 2016, Haematologica.

[7]  F. Leebeek,et al.  Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications , 2016, Journal of thrombosis and haemostasis : JTH.

[8]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[9]  Philip Sedgwick,et al.  Understanding the Hawthorne effect , 2015, BMJ : British Medical Journal.

[10]  S. Polinder,et al.  The “OPTI-CLOT” trial , 2015, Thrombosis and Haemostasis.

[11]  Kathleen A. Johnson,et al.  Burden of illness: direct and indirect costs among persons with hemophilia A in the United States , 2015, Journal of medical economics.

[12]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[13]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[14]  Kathleen A. Johnson,et al.  Costs of care in hemophilia and possible implications of health care reform. , 2011, Hematology. American Society of Hematology. Education Program.

[15]  S. Björkman.  Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  S. Jönsson,et al.  Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.

[17]  K. Kurnik,et al.  Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  M. Walsh,et al.  Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  D. Dingli,et al.  Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma‐derived or recombinant factor VIII concentrates , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.

[21]  R. Ljung,et al.  Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A , 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  Scott T. Miller,et al.  Surgery and anesthesia in sickle cell disease. Cooperative Study of Sickle Cell Diseases. , 1995, Blood.

[23]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[24]  J. Over.  Methodology of the one-stage assay of Factor VIII (VIII:C). , 2009, Scandinavian journal of haematology. Supplementum.

[25]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.